PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2019.7262020523973-986RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast CancerTian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yaohttp://e-crt.org/upload/pdf/crt-2019-726.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2019.726, http://e-crt.org/upload/pdf/crt-2019-726.pdf
Frontiers in Oncology10.3389/fonc.2019.0137720199Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic CancerChen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yaohttps://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
British Journal of Pharmacology10.1111/bph.132112015172174228-4237Therapeutic targets of triple-negative breast cancer: a reviewVinayak S Jamdade, Nikunj Sethi, Nitin A Mundhe, Parveen Kumar, Mangala Lahkar, Neeraj Sinhahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbph.13211, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbph.13211, http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.13211/fullpdf
Breast Cancer Research10.1186/s13058-015-0524-02015171Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapyBetsy T Kren, Gretchen M Unger, Md J Abedin, Rachel I Vogel, Christine M Henzler, Khalil Ahmed, Janeen H Trembleyhttp://link.springer.com/content/pdf/10.1186/s13058-015-0524-0.pdf, http://link.springer.com/article/10.1186/s13058-015-0524-0/fulltext.html, http://link.springer.com/content/pdf/10.1186/s13058-015-0524-0, http://link.springer.com/content/pdf/10.1186/s13058-015-0524-0.pdf
Breast Cancer Research10.1186/bcr919200465New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitorsNancy U Lin, Eric P Winerhttp://link.springer.com/article/10.1186/bcr919/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr919.pdf, http://link.springer.com/content/pdf/10.1186/bcr919.pdf
Current Breast Cancer Reports10.1007/s12609-015-0192-1201574215-223Potential Therapeutic Targets in Triple Negative Breast CancerHamdy A. Azim, Hatem A. Azimhttp://link.springer.com/content/pdf/10.1007/s12609-015-0192-1.pdf, http://link.springer.com/article/10.1007/s12609-015-0192-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12609-015-0192-1, http://link.springer.com/content/pdf/10.1007/s12609-015-0192-1.pdf
Tyrosine Kinases as Druggable Targets in Cancer10.5772/intechopen.860822019Noncoding RNAs as Predictive Biomarkers of Therapeutic Response to Tyrosine Kinase Inhibitors in Metastatic CancerJulia Kovacova, Ondrej Slabyhttp://www.intechopen.com/download/pdf/66849
Cancer Cell International10.1186/s12935-018-0597-92018181B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancerLing Wang, Chao Yang, Xin-bo Liu, Li Wang, Fu-biao Kanghttp://link.springer.com/content/pdf/10.1186/s12935-018-0597-9.pdf, http://link.springer.com/article/10.1186/s12935-018-0597-9/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12935-018-0597-9.pdf
Breast Cancer Research10.1186/bcr32242012144Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of MetKelly L Mueller, Julie M Madden, Gina L Zoratti, Charlotte Kuperwasser, Karin List, Julie L Boernerhttp://link.springer.com/content/pdf/10.1186/bcr3224.pdf, http://link.springer.com/article/10.1186/bcr3224/fulltext.html, http://link.springer.com/content/pdf/10.1186/bcr3224.pdf
The Breast10.1016/j.breast.2017.01.006201736102Have all triple-negative breast cancer patients worse breast cancer-specific survival?Kadri Altundaghttps://api.elsevier.com/content/article/PII:S0960977617300061?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977617300061?httpAccept=text/plain